Please assess the completion status of the following clinical trial:

Trial Title: Helicobacter Pylori Eradication With Different Bismuth Quadruple Therapies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18\~75,both gender.~* Patients with upper gastrointestinal symptoms and with documented H.pylori infection.~* Patients are willing to receive eradication treatment.~* Women are eligible if they are not pregnant or nursing, and if they are of childbearing potential they are required to use medically acceptable contraception for the duration of the study and 30 days thereafter.~Exclusion Criteria:~* Patients are excluded if they have previously used antibiotics to eradicate adequately recorded infection with H. pylori.~* Contraindications to study drugs.~* Substantial organ impairment, severe or unstable cardiopulmonary or endocrine disease.~* Constant use of anti-ulcer drugs ( including taking proton-pump.inhibitors(PPI) within 2 weeks before the \[13C\] urea breath test),antibiotics or bismuth complexes (more than 3 times /1 month before screening).~* Patients were diagnosed with gastroduodenal ulcer and MALTlymphoma.~* Pregnant or lactating women.~* Underwent upper gastrointestinal Surgery.~* Patients with Barrett esophageal or highly atypical hyperplasia, have symptom of dysphagia.~* Evidence of bleeding or iron efficiency anemia.- Page 3 of 4 \[DRAFT\] -~* A history of malignancy.~* Drug or alcohol abuse history in the past 1 year.~* Systemic use of corticosteroids, non steroidal anti-inflammatory drugs,anticoagulants, platelet aggregation inhibitors (except the use of aspirin for less than 100 mg/d).~* Patients who has psychological problem or poor compliance.~* Enrolled in other clinical trials in the past 3 months.~* Refuse to sign informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Bismuth potassium citrate containing quadruple therapy (Type: ACTIVE_COMPARATOR): Bismuth potassium citrate 220 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
- Colloidal pectin bismuth capsules containing quadruple therapy (Type: ACTIVE_COMPARATOR): Colloidal pectin bismuth capsules 200 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
- Colloidal pectin bismuth particles A quadruple therapy (Type: ACTIVE_COMPARATOR): Colloidal pectin bismuth particles 150 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
- Colloidal pectin bismuth particles B quadruple therapy (Type: ACTIVE_COMPARATOR): Colloidal pectin bismuth particles 300 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).